Centessa Announces Q3 EPS of 41 Cents, Exceeding Consensus Estimate of 39 Cents
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Should l Buy CNTA?
Progress on OX2R Agonist Program: Centessa's ORX750 shows promising results as a potential best-in-class OX2R agonist for treating NT1, NT2, and IH, achieving significant outcomes in key measures during Phase 2a trials.
Safety and Efficacy: The clinical data indicates a favorable safety profile and a wide therapeutic window for ORX750, with plans to initiate a registrational program in Q1 2026.
Advancements in Other Candidates: ORX142 has demonstrated a differentiated profile in Phase 1 studies, leading to plans for patient studies starting in Q1 2026, while ORX489 is progressing through IND enabling studies.
Leadership in Neuroscience: Centessa aims to establish a strong position in the emerging class of orexin agonists, building a long-term growth platform in neuroscience with multiple candidates in development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNTA
Wall Street analysts forecast CNTA stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.860
Low
27.00
Averages
38.75
High
62.00
Current: 26.860
Low
27.00
Averages
38.75
High
62.00
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Comparison: Centessa vs. Vertex Pharmaceuticals
- Centessa's Drug Potential: Centessa Pharmaceuticals is developing ORX750 for narcolepsy type 1, type 2, and idiopathic hypersomnia, which could become a foundational therapy due to its broad applicability and novel mechanism; however, it has yet to demonstrate efficacy in late-stage studies, posing significant risks.
- Market Performance Comparison: Centessa's shares have significantly outperformed broader equities over the past year, with a current market cap of $3.6 billion, yet as a smaller biotech without any products on the market and ongoing losses, it carries high investment risks.
- Vertex's Stability: Vertex Pharmaceuticals has successfully revolutionized the standard of care for cystic fibrosis, generating consistent revenue and profits with a market cap of $123 billion, making it a safer investment option compared to Centessa.
- Future Development Prospects: Vertex is advancing several late-stage pipeline candidates, including zimislecel for type 1 diabetes, which is expected to seek regulatory approval this year; successful outcomes could further solidify its market position and attract investors with average risk tolerance.
See More
Commodore Capital Reduces Stake in Centessa Pharmaceuticals
- Stake Reduction Details: According to a February 17, 2026 SEC filing, Commodore Capital sold 1,850,000 shares of Centessa Pharmaceuticals in Q4, with an estimated transaction value of approximately $46.86 million, indicating a cautious outlook on the company's future prospects.
- Position Value Decline: This sale resulted in a $44.10 million decrease in Commodore's quarter-end position value in Centessa, reflecting not only the sale activity but also the impact of price movements, suggesting a potential waning confidence in the stock.
- Ownership Ratio Adjustment: Following the reduction, Commodore's stake in Centessa dropped to 1.66%, indicating a significant shift in its investment strategy that may influence future investment decisions and portfolio management.
- Market Performance Analysis: Despite Centessa's stock price rising 53.4% over the past year, Commodore's divestment suggests a capital redeployment strategy, prompting investors to monitor the company's strategic transformation under new CEO leadership and its implications for future performance.
See More
Braidwell Acquires Significant Stake in Centessa Pharmaceuticals
- Stake Acquisition: On February 17, 2026, Braidwell disclosed the acquisition of 2,188,320 shares of Centessa Pharmaceuticals for approximately $54.73 million, indicating confidence in the company, although this stake represents only 1.75% of its reportable assets.
- Stock Performance: As of February 17, 2026, Centessa's stock price stood at $24.94, reflecting a 53.4% increase over the past year, significantly outperforming the S&P 500 by 34.19 percentage points, indicating positive market expectations for its clinical pipeline.
- Company Overview: Centessa focuses on developing clinical-stage drug candidates, including Lixivaptan for polycystic kidney disease and SerpinPC for hemophilia, aiming to create value through successful drug approvals and commercialization, addressing the needs of patients with rare and autoimmune diseases.
- Strategic Shift: The appointment of Mario Accardi as CEO underscores a sharpened focus on OX2R agonists, suggesting potential expansion into neuropsychiatric indications, despite the inherent volatility in clinical-stage neuroscience.
See More
Tanager Wealth Management Fully Exits Centessa Pharmaceuticals Stake
- Complete Exit: Tanager Wealth Management disclosed in a January 26 SEC filing that it sold its entire stake in Centessa Pharmaceuticals, totaling 598,044 shares in the fourth quarter, with an estimated transaction value of $14.50 million, indicating a complete liquidation of its investment in the company.
- Asset Management Shift: This exit means that Centessa now represents 0% of Tanager's reportable 13F AUM, down from 1.5% in the previous quarter, reflecting a significant reduction in confidence towards the stock.
- Improving Fundamentals: Despite Tanager's exit, Centessa's fundamentals are improving, as evidenced by its latest earnings report showing $349 million in cash and investments, along with a $250 million investment received in November, indicating a strengthening financial position.
- Market Performance Comparison: Centessa's stock price has risen approximately 56.7% over the past year, significantly outperforming the S&P 500's roughly 14% gain during the same period, highlighting its potential and market recognition in the biotechnology sector.
See More
Tanager Wealth Management Exits Entire CNTA Position
- Position Change: Tanager Wealth Management completely exited its position in Centessa Pharmaceuticals (CNTA) in Q4, selling 598,044 shares, resulting in a $14.50 million decrease in position value, reflecting both stock price movement and the sale itself.
- Asset Management Ratio Decline: This exit reduced CNTA's representation in Tanager Wealth Management's reported AUM from 1.5% to 0%, highlighting the fund's risk management strategy regarding individual biotech stocks.
- Market Performance Comparison: As of January 26, CNTA shares were priced at $25.73, up approximately 56.7% over the past year, significantly outperforming the S&P 500's roughly 14% gain during the same period, indicating market confidence in its fundamentals.
- Improving Company Fundamentals: Centessa Pharmaceuticals reported $349 million in cash and investments in its latest earnings release, along with $250 million from investors in November, showcasing its robust development in the clinical-stage biotech sector.
See More
Centessa Pharmaceuticals Presents New OX2R Agonist Data, Enhancing Mood in Depression Models
- New Data Presentation: Centessa Pharmaceuticals showcased preclinical data on OX2R agonists at the ACNP annual meeting, demonstrating significant improvements in behavioral despair and wakefulness in depression animal models, indicating potential for rapid mood enhancement.
- Clear Strategic Direction: CEO Mario Alberto Accardi, PhD, emphasized the company's commitment to exploring new therapeutic options through its multi-asset OX2R agonist pipeline, addressing mood symptoms and excessive daytime sleepiness, showcasing foresight in the neuroscience field.
- Clinical Trial Progress: The OX2R agonist ORX750 is currently undergoing Phase 2 CRYSTAL-1 study aimed at treating sleep-wake disorders, including narcolepsy, indicating Centessa's potential expansion into high unmet clinical needs.
- Solid Scientific Foundation: The presented research supports the scientific basis for OX2R agonists as novel treatment modalities, potentially offering new therapeutic options for various neuropsychiatric disorders, further solidifying Centessa's leadership in this domain.
See More
Investment Comparison: Centessa vs. Vertex Pharmaceuticals
- Centessa's Drug Potential: Centessa Pharmaceuticals is developing ORX750 for narcolepsy type 1, type 2, and idiopathic hypersomnia, which could become a foundational therapy due to its broad applicability and novel mechanism; however, it has yet to demonstrate efficacy in late-stage studies, posing significant risks.
- Market Performance Comparison: Centessa's shares have significantly outperformed broader equities over the past year, with a current market cap of $3.6 billion, yet as a smaller biotech without any products on the market and ongoing losses, it carries high investment risks.
- Vertex's Stability: Vertex Pharmaceuticals has successfully revolutionized the standard of care for cystic fibrosis, generating consistent revenue and profits with a market cap of $123 billion, making it a safer investment option compared to Centessa.
- Future Development Prospects: Vertex is advancing several late-stage pipeline candidates, including zimislecel for type 1 diabetes, which is expected to seek regulatory approval this year; successful outcomes could further solidify its market position and attract investors with average risk tolerance.
See More
Commodore Capital Reduces Stake in Centessa Pharmaceuticals
- Stake Reduction Details: According to a February 17, 2026 SEC filing, Commodore Capital sold 1,850,000 shares of Centessa Pharmaceuticals in Q4, with an estimated transaction value of approximately $46.86 million, indicating a cautious outlook on the company's future prospects.
- Position Value Decline: This sale resulted in a $44.10 million decrease in Commodore's quarter-end position value in Centessa, reflecting not only the sale activity but also the impact of price movements, suggesting a potential waning confidence in the stock.
- Ownership Ratio Adjustment: Following the reduction, Commodore's stake in Centessa dropped to 1.66%, indicating a significant shift in its investment strategy that may influence future investment decisions and portfolio management.
- Market Performance Analysis: Despite Centessa's stock price rising 53.4% over the past year, Commodore's divestment suggests a capital redeployment strategy, prompting investors to monitor the company's strategic transformation under new CEO leadership and its implications for future performance.
See More
Braidwell Acquires Significant Stake in Centessa Pharmaceuticals
- Stake Acquisition: On February 17, 2026, Braidwell disclosed the acquisition of 2,188,320 shares of Centessa Pharmaceuticals for approximately $54.73 million, indicating confidence in the company, although this stake represents only 1.75% of its reportable assets.
- Stock Performance: As of February 17, 2026, Centessa's stock price stood at $24.94, reflecting a 53.4% increase over the past year, significantly outperforming the S&P 500 by 34.19 percentage points, indicating positive market expectations for its clinical pipeline.
- Company Overview: Centessa focuses on developing clinical-stage drug candidates, including Lixivaptan for polycystic kidney disease and SerpinPC for hemophilia, aiming to create value through successful drug approvals and commercialization, addressing the needs of patients with rare and autoimmune diseases.
- Strategic Shift: The appointment of Mario Accardi as CEO underscores a sharpened focus on OX2R agonists, suggesting potential expansion into neuropsychiatric indications, despite the inherent volatility in clinical-stage neuroscience.
See More
Tanager Wealth Management Fully Exits Centessa Pharmaceuticals Stake
- Complete Exit: Tanager Wealth Management disclosed in a January 26 SEC filing that it sold its entire stake in Centessa Pharmaceuticals, totaling 598,044 shares in the fourth quarter, with an estimated transaction value of $14.50 million, indicating a complete liquidation of its investment in the company.
- Asset Management Shift: This exit means that Centessa now represents 0% of Tanager's reportable 13F AUM, down from 1.5% in the previous quarter, reflecting a significant reduction in confidence towards the stock.
- Improving Fundamentals: Despite Tanager's exit, Centessa's fundamentals are improving, as evidenced by its latest earnings report showing $349 million in cash and investments, along with a $250 million investment received in November, indicating a strengthening financial position.
- Market Performance Comparison: Centessa's stock price has risen approximately 56.7% over the past year, significantly outperforming the S&P 500's roughly 14% gain during the same period, highlighting its potential and market recognition in the biotechnology sector.
See More
Tanager Wealth Management Exits Entire CNTA Position
- Position Change: Tanager Wealth Management completely exited its position in Centessa Pharmaceuticals (CNTA) in Q4, selling 598,044 shares, resulting in a $14.50 million decrease in position value, reflecting both stock price movement and the sale itself.
- Asset Management Ratio Decline: This exit reduced CNTA's representation in Tanager Wealth Management's reported AUM from 1.5% to 0%, highlighting the fund's risk management strategy regarding individual biotech stocks.
- Market Performance Comparison: As of January 26, CNTA shares were priced at $25.73, up approximately 56.7% over the past year, significantly outperforming the S&P 500's roughly 14% gain during the same period, indicating market confidence in its fundamentals.
- Improving Company Fundamentals: Centessa Pharmaceuticals reported $349 million in cash and investments in its latest earnings release, along with $250 million from investors in November, showcasing its robust development in the clinical-stage biotech sector.
See More
Centessa Pharmaceuticals Presents New OX2R Agonist Data, Enhancing Mood in Depression Models
- New Data Presentation: Centessa Pharmaceuticals showcased preclinical data on OX2R agonists at the ACNP annual meeting, demonstrating significant improvements in behavioral despair and wakefulness in depression animal models, indicating potential for rapid mood enhancement.
- Clear Strategic Direction: CEO Mario Alberto Accardi, PhD, emphasized the company's commitment to exploring new therapeutic options through its multi-asset OX2R agonist pipeline, addressing mood symptoms and excessive daytime sleepiness, showcasing foresight in the neuroscience field.
- Clinical Trial Progress: The OX2R agonist ORX750 is currently undergoing Phase 2 CRYSTAL-1 study aimed at treating sleep-wake disorders, including narcolepsy, indicating Centessa's potential expansion into high unmet clinical needs.
- Solid Scientific Foundation: The presented research supports the scientific basis for OX2R agonists as novel treatment modalities, potentially offering new therapeutic options for various neuropsychiatric disorders, further solidifying Centessa's leadership in this domain.
See More
